Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$29.83 USD

29.83
4,829,456

+0.57 (1.95%)

Updated May 3, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (196 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) Announces Positive Results From PNH Studies

by Zacks Equity Research

Roche (RHHBY) crovalimab achieves disease control in paroxysmal nocturnal hemoglobinuria patients in the phase III COMMODORE 1 and COMMODORE 2 studies.

Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement

by Zacks Equity Research

An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.

Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod

by Zacks Equity Research

Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.

Dr. Reddy's (RDY) Meets Goals in Actemra Biosimilar Study

by Zacks Equity Research

Dr. Reddy's (RDY) announces meeting primary and secondary endpoints in the phase I study of its proposed tocilizumab biosimilar for the treatment of rheumatoid arthritis in adults.

AstraZeneca (AZN) Anticoagulant Drug Study Meets Efficacy Goal

by Zacks Equity Research

At the interim analysis, AstraZeneca's (AZN) drug Andexxa showed superior hemostatic efficacy or in other words improved control of bleeding with targeted anticoagulation reversal versus usual care.

Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis

by Zacks Equity Research

Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.

Sanofi (SNY) NextGen Multiple Sclerosis Drug Meets Phase II Goal

by Zacks Equity Research

Sanofi's (SNY) phase II study on its novel investigational anti-CD40L antibody, frexalimab, meets the primary endpoint.

Kinjel Shah headshot

5 Large Drug Stocks to Watch From a Thriving Industry

by Kinjel Shah

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

by Zacks Equity Research

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review

by Zacks Equity Research

The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.

Alimera (ALIM) Completes Enrollment in Eye Disease Study

by Zacks Equity Research

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.

Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq

by Zacks Equity Research

Alimera's (ALIM) stock jumps 19.4% after the company inks a deal with Eyepoint to acquire additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq

Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now

by Zacks Equity Research

ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates

by Kinjel Shah

FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.

Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study

by Zacks Equity Research

Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.

Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel

by Zacks Equity Research

The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.

Eli Lilly (LLY) Stock Up 18.7% YTD, New Drugs Key to Growth

by Zacks Equity Research

Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.

Kinjel Shah headshot

Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates

by Kinjel Shah

Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.

Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

by Zacks Equity Research

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.

Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline

by Zacks Equity Research

Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.